AI Can Accelerate Discovery — Development Still Decides What Advances
AI will continue changing how small molecules are discovered, but the candidates that generate the most interest in silico still have to succeed under real development conditions.
Elizabeth Hickman
Elizabeth Hickman serves as Chief Executive Officer at AustinPx, a leading contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement of orally delivered small molecule drug candidates. Elizabeth brings over two decades of expertise in the biotech and pharmaceutical sectors, formerly serving in leadership positions for West Pharmaceutical Services, Catalent, and Pii. Elizabeth holds a BA in Microbiology from The University of Texas at Austin and an MBA in Marketing from San Diego State University.